DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2028

Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
DRUG

DEB-TACE+HAIC

"CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.~RALOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; Raltitrexed, 3 mg/m2 infusion for 0.5 hour."

DRUG

DEB-TACE

CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.

Trial Locations (1)

510260

RECRUITING

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
collaborator

Zhongshan People's Hospital, Guangdong, China

OTHER

collaborator

Guangzhou Development District Hospital

UNKNOWN

collaborator

The Affiliated Shunde Hospital of Jinan University

UNKNOWN

lead

Second Affiliated Hospital of Guangzhou Medical University

OTHER